Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Martek Biosciences Corp.
Bear, Stearns analyst Scott Shevick began coverage with a "hold." The company's products
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury